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Sustained Hemodynamic Improvement During Long-Term Therapy
With Levodopa in Heart Failure: Role of Plasma Catecholamines
SOL I. RAJFER, MD, FACC, JAMES D. ROSSEN, MD, JOHN W. NEMANICH, MD,
FRANK L. DOUGLAS, MD, PHD, FETIMA DAVIS, RN, JOACHIM OSINSKI, MS
Chicago, Illinois
Long-term therapy with oral sympathomimetic amines
in patients with heart failure has been limited by the
eventual development of diminished pharmacologic ef-
ficacy. However, a previous investigation in five subjects
with heart failure suggested that long-term ingestion of
levodopa, which is decarboxylated endogenously to do-
pamine, produces a sustained improvement in cardiac
function. In the present study, levodopa was adminis-
tered orally (1.5 to 2.0 g) to 14 patients with heart failure
while hemodynamic responses and plasma catechol-
amines were monitored. Initially, an increase in cardiac
index and stroke volume index was accompanied by a
decline in systemic vascular resistance, mean pulmonary
capillary wedge pressure and mean right atrial pressure.
Heart rate and mean arterial pressure were unchanged.
Plasma concentrations of dopamine rose substantially
after drug ingestion and correlated significantly with
changes in cardiac index (r = 0.73, P < 0.05).
The administration of dopamine to patients with heart failure
improves the deranged circulatory state through activation
of beta.cadrenoceptors (positive inotropic action) and
dopamine, (DAd receptors (renal artery vasodilation) produces
a natriuresis (l,2). Dopamine is not effective when admin-
istered orally and thus is of limited value in the long-term
treatment of patients with heart failure. N-methyldopamine
is one of the few modifications of the dopamine molecule
that retains agonist activity at the beta.vadrenoceptor and
DA 1 receptor (3,4), and appreciable plasma levels of N-
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After 12 weeksof treatment with levodopa, the changes
in cardiac index, stroke volume index, systemic vascular
resistance and plasma dopamine levels persisted (n =
12 patients). Moreover, a significant decrease occurred
in the heart rate at rest. Although there was an initial
tendency for plasma norepinephrine concentrations to
increase, a return to control levels was documented after
long-term treatment. Thus, tolerance to the hemody-
namic actions of levodopa did not develop during long-
term administration of the drug.
The hemodynamic responses observed can be as-
cribed to the activation of betaj-adrenoceptors and
dopamine, receptors by dopamine generated from levo-
dopa. The dopamine, activity of dopamine does not ap-
pear to be responsible for the improvement in cardiac
performance produced by levodopa.
(J Am Coil Cardiol1987;10:1286-93)
methyldopamine are achieved when it is ingested as the
diisobutyric ester, ibopamine (5). However, long-term ther-
apy with ibopamine in patients with heart failure is asso-
ciated with an attenuation of the initial hemodynamic re-
sponses to the drug (5).
In contrast, we failed to observe the development of
tolerance to the hemodynamic effects of levodopa, which
is converted endogenously to dopamine, during long-term
oral administration to a small group of patients (five patients)
with congestive heart failure (6). Therefore, the present
investigation was undertaken to confirm our initial obser-
vations on the hemodynamic actions of levodopa when ad-
ministered long-term to a larger group of patients with heart
failure and to assess the role of plasma catecholamines and
the sympathetic nervous system in determining the clinical
efficacy of this drug.
Methods
Study patients (Table 1). The study group consisted of
12 men and 2 women with congestive heart failure of at
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Table l. Clinical Characteristics of the 14 Study Patients
Patient LVEF NYHA
No. Age (yr) & Sex Diagnosis (%) Functional Class
I 65M Idiopathic cardiomyopathy 28 III
2 56M Ischemic heart disease 20 III
3 66F Idiopathic cardiomyopathy 32 III
4 61M Idiopathic cardiomyopathy 10 IV
5 56M Idiopathic cardiomyopathy 17 IV
6 65F Ischemic heart disease 23 III
7 25M Idiopathic cardiomyopathy 24 IV
8 21M Idiopathic cardiomyopathy 12 II
9 55M Ischemic heart disease 35 III
10 39M Idiopathic cardiomyopathy 13 1II
II 68M Idiopathic cardiomyopathy 12 III
12 71M Ischemic heart disease 21 1II
13 32M Idiopathic cardiomyopathy 27 III
14 60M Idiopathic cardiomyopathy 15 III
F = female; LVEF = left ventricularejection fraction: M = male: NYHA = New York Heart Association.
least 3 months' duration. They ranged in age from 21 to 71
years (mean ± SEM 53 ± 4). Three patients were classified
as meeting the criteria for New York Heart Association
functional class IV, 10 were in class III, and I was in class
II. The cause of heart failure was ischemic heart disease in
4 patients and idiopathic cardiomyopathy in 10. Atrial fi-
brillation was present in 2 patients; normal sinus rhythm
was present in the other 12. No patient had experienced
unstable angina pectoris or acute myocardial infarction within
the preceding 12 weeks. All patients had angiographic, nu-
clear scintigraphic or echocardiographic evidence of severe
left ventricular dysfunction (mean ejection fraction 21 ±
2%) and cardiomegaly visible on a chest roentgenogram.
Written informed consent was obtained from each pa-
tient. The protocol was approved by the University of Chi-
cago Clinical Investigation Committee.
Short-Term Hemodynamic Evaluation
Hemodynamic measurements. Each patient underwent
right heart catheterization with placement of a balloon-tipped
thermodilution catheter in the pulmonary artery so that bal-
loon inflation allowed recording of the pulmonary capillary
wedge pressure. After establishment of the identity of the
pulmonary artery diastolic pressure with mean pulmonary
capillary wedge pressure, the former was monitored as an
index of the mean pulmonary capillary wedge pressure.
Systemic arterial pressure was measured through a cannula
inserted into the radial artery. Right atrial, pulmonary artery
and systemic arterial pressures were monitored continuously
using Hewlett-Packard 1290A quartz pressure transducers
interfaced with Hewlett-Packard 78534A recording units.
Mean pressures were determined by electronic integration.
The electrocardiogram (ECG) was monitored continuously,
and the heart rate was measured from the simultaneous ECG
signal. Cardiac output was determined by the thermodilution
method using an Edwards Laboratories computer (model
9520A) and averaging three replicate determinations that
varied < 10% (if the variance was> 10%, five consecutive
determinations were averaged).
Derived hemodynamic variables were calculated as fol-
lows: cardiac index (liters/min per rrr') = cardiac output
(Iiters/min)/body surface area (rrr'); sttoke volume index
(mllbeat per rrr') = cardiac index/heart rate (beats/min);
systemic vascular resistance (dynes-s-cm r') = 80 [mean
systemic arterial pressure (mm Hg) - mean right atrial
pressure (mm Hg)]/cardiac output.
Drug administration. Prior experience with levodopa
therapy in Parkinson's disease has shown that initial inges-
tion of the drug at doses > 250 mg will induce emesis in a
substantial number of patients and that this can be avoided
by an incremental dose schedule. Thus, levodopa was ad-
ministered orally in increments of I g every 2 days, begin-
ning with 250 mg four times a day, until a total daily dose
of 6 g was achieved with no side effects; all subjects com-
pleted the titration phase. The patients also received a daily
dose of 50 mg of pyridoxine hydrochloride, an essential
cofactor for the decarboxylation of levodopa to dopamine.
After four doses of 1.5 g of levodopa, the drug was withheld
for 24 to 36 hours. After this washout period, patients were
studied in the recumbent, fasting state without premedica-
tion. Diuretics were discontinued 24 hours before the study
period and digitalis and pyridoxine were withheld on the
morning of the study. Vasodilators were discontinued at
least 36 hours before the acquisition of hemodynamic mea-
surements. One patient who required a continuous infusion
of dopamine (2 ltg/kg per min) to prevent rapid clinical
deterioration was enrolled in the study; dopamine was dis-
continued when a daily dose of 3 g of Ievodopa was attained.
The thermodilution and arterial catheters were inserted
16 to 24 hours before the study period. Control hemody-
namic measurements were obtained at 30 minute intervals
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until a stable baseline was established « 10% variation).
Levodopa was then administered orally in a dose of 1.5 g;
one patient received 2 g. Hemodynamic measurements were
repeated 0.5, I, 2, 3, 4 and 6 hours after drug ingestion.
Measurements of plasma concentrations of dopamine
and norepinephrine. Plasma concentrations of free do-
pamine and norepinephrine were determined immediately
before and 0.5, 1, 2, 3, 4 and 6 hours after the administration
of levodopa. Blood samples for analysis were obtained from
the right atrium and placed in chilled heparinized glass tubes
containing sodium metabisulfite. The plasma was separated
and stored at - 20°C until assayed. Dopamine and norepi-
nephrine were extracted from I ml of plasma by a micro-
modification of the aluminum oxide procedure of Anton and
Sayre (7). They were separated by high performance liquid
chromatography on a C-18 reverse phase column (Ultra-
sphere-DDS,S j.Lm, Altex) with a mobile phase consisting
of 0.075 M monochloroacetic acid, 2.0 mM disodium EDTA,
1.0 mM sodium octyl sulfate and 12% methanol, pH 2.95,
and a flow rate of 0.7 mllmin. Dopamine and norepinephrine
were detected electrochemically with a Bioanalytical Sys-
tems LC-4B detector at 0.7 V using a glassy carbon elec-
trode.
Evaluation of Long-Term Treatment
Drug regimen. After completion of the short-term study
the catheters were removed. The patients resumed their pre-
study dosages of diuretics, digitalis and antiarrhythmic agents.
Levodopa (1.5 to 2.0 g) was added to the drug regimen and
ingested four times a day. Pyridoxine hydrochloride (50 mg)
was also ingested daily. Patients were then discharged from
the hospital and were evaluated every 2 to 4 weeks in the
outpatient clinic.
Repeat hemodynamic evaluation. Thirteen of the 14
patients completed 12 weeks of therapy with levodopa; 12
agreed to undergo repeat hemodynamic evaluation (3 pa-
tients deferred repeat evaluation until the completion of 8
to 14 months of therapy). Catheters were placed 16 to 24
hours before the hemodynamic study as previously de-
scribed. Diuretics were discontinued 24 hours before the
investigation; digitalis and pyridoxine were withheld on the
morning of the study. Baseline hemodynamic measurements
were obtained after an overnight fast and 10 to 12 hours
after the last dose of levodopa. The maintenance dose of
levodopa was given orally, and hemodynamic measure-
ments were repeated 0.5, 1, 2, 3, 4 and 6 hours after drug
ingestion. Plasma concentrations of dopamine (n = II) and
norepinephrine (n = 9) were measured each time hemo-
dynamic measurements were obtained.
Data analysis. All values are expressed as the mean
value ± SEM. Statistical analyses involving comparisons
of data obtained before and after ingestion of levodopa were
accomplished by the use of the r-test for paired samples and
the Bonferroni correction for multiple comparisons (8). Sta-
tistical significance was accepted at a p value <0.05/k,
where k = the number of comparisons performed.
Baseline measurements obtained during the short- and
long-term studies were compared using the t-test for paired
samples. The relation between dopamine or norepinephrine
levels and cardiac index as well as that between dopamine
and norepinephrine concentrations was assessed by com-
puting the correlation coefficient for each patient and then
deriving a mean correlation coefficient with Fisher's z trans-
formation (9). The contribution of plasma dopamine and
norepinephrine levels to the determination of cardiac per-
formance was examined by multiple linear regression anal-
ysis. A p value <0.05 was considered indicative of statis-
tical significance.
Results
Short-Term Effects of Levodopa
Short-term hemodynamic measurements (Table 2).
The cardiac index increased significantly 0.5 hour after
ingestion of levodopa and continued to rise to a peak value
at I hour. The maximal value achieved, 2.66 ± 0.15 liters/
min per rrr', represented a 29% increment (p < 0.0083)
above the baseline measurement of 2.06 ± 0.10 liters/min
per m". The cardiac index remained elevated throughout the
measurement period of 6 hours, although it was not signif-
icantly different from the control value 6 hours after the
administration of levodopa. Concomitantly, stroke volume
index rose from a baseline value of 24 ± 2 to a maximum
of 30 ± 2 mllbeat per m2 (p < 0.0083) at 1 hour. Significant
improvement in the stroke volume index was observed up
to 4 hours after drug administration.
Systemic vascular resistance declined progressively from
a control value of 1,832 ± 146 dynes-s-cm - 5 to a nadir of
1,366 ± 107 dynes-s-cm -5 (p < 0.0083) at I hour. The
decline in systemic vascular resistance persisted throughout
the observation period, although it was not significant at 6
hours. The mean arterial pressure and heart rate did not
change significantly after ingestion of levodopa.
The elevated. baseline mean pulmonary capillary wedge
pressure of 23 ± 1 mm Hg declined to 19 ± I mm Hg (p
< 0.0083) 2 hours after the administration of levodopa and
remained significantly depressed throughout the study pe-
riod. The mean right atrial pressure also decreased gradually
from a control value of 6 ± I to 4 ± 1 mm Hg (p <
0.0083) at 2 hours; the reduction in right atrial pressure
persisted for the next 4 hours.
Plasma concentrations of dopamine and norepineph-
rine. The plasma concentration of dopamine rose from a
baseline value of 1.0 ± 0.2 ng/ml to a maximum of 43 ±
16 ng/ml (p < 0.0083) at 0.5 hour and then declined grad-
ually during the subsequent 5.5 hours. The peak plasma
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Table 2. Hemodynamic Measurements , Plasma Dopamine Levels, and Plasma Norepinephrine Levels After Short-Term
Administration of Levodopa in 14 Patients
Hours After Levodopa Ingestion
Baseline 0.5 2 3 4 6
Cardiac index 2.06 ± 0. 10 2.38 ± 0. 15* 2.66 ± 0. 15* 2.44 ± 0. 13* 2.38 ± 0. 16* 2.43 ± 0. 13* 2.26 ± 0. 15
(liters/min per rrr')
Heart rate (beats/min) 90 ± 5 89 ± 5 92 ± 5 89 ± 5 90 ± 5 87 ± 5 88 ± 5
Stroke volume index 24 ± 2 28 ± 2* 30 ± 2* 28 ± 2* 27 ± 2 29 ± 3* 27 ± 3
(rnl/beat per rrr' )
Mean arterial pressure 87 ± 3 86 ± 2 83 ± 2 81 :±: 2 82 ± 2 82 ::!: 2 82 ± 2
(mm Hg)
SVR (dynes-s-cm 5) 1,832 ::!: 146 I ,571 :± I 10* 1,366 :± 107* 1.455 :± 88* 1.530 :± 11 5* 1,452 :± 99* 1,591 ± 105
PCWP (rnrn Hg) 23 ::!: I 22 :± 2 20 :± I 19 ± 1* 19 ± 2* 18 ± 1* 19 ± 1*
RAP (mm Hg) 6 ± I 6 ± I 5 :± I 4 ± 1* 4 ± 1* 4 ± 1* 4 ± 1*
Plasma dopamine 1 0 ± 0.2 43 :!: 16* 33 ± 8* 26 ± 6* 18 :± 5* 12 :± 2* 6 :!: 2*
(ng/m\)
Plasma 617 ± III 977 ± 159 1.076 :!: 256 995 :!: 240 971 ± 263 1,234 ± 417 650 ± 198
norepinephrine
(pg/ml)
Values are mean ± SEM. PCWP = mean pulmonary capillary wedge pressure; RAP = mean right atrial pressure; SVR = systemic vascular
resistance.
*p < 0.0083 for the difference from the baseline value.
Table 3. Baseline Hemodynamic Measurements Obtained
During the Short- and Long-Term Studies in 12 Patients With
Heart Failure
Values are mean ± SEM.
*p < 0.05 for the difference from the baseline value for the initial
study.
Effects of Long-Term Levodopa Therapy
Clinical observations. Thirteen patients completed 12
weeks of therapy with levodopa. These 13 patients reported
symptomatic improvement: 12 subjects attained New York
Heart Association functional class II and the condition of
one patient improved from class IV to class III. A gradual
deterioration in the clinical status of the remaining patient
prompted his withdrawal from the study after II weeks of
therapy. On enrollment in the study. this patient had been
receiving a continuous infusion of dopamine at a rate of 2
fLg/kg per min and discontinuing dopamine would have
resulted in rapidclinical deterioration. This patientexhibited
concentration of dopamine for each individual occurred within
2 hours of drug ingestion in 12 patients and afterward in
the other 2 subjects; the mean value of these peak levels
was 61 ± 14 ng/ml. Changes in cardiac index that occurred
after ingestion of levodopa demonstrated a signifi cant cor-
relation with plasma levels of generated dopamine (r =
0.73, P < 0.05).
The mean baseline plasma norepinephrine concentration
was elevated at 617 ± III pg/ml. The administration of
levodopa was accompanied by an increase in plasma nor-
epinephrine levels that did not achieve statistical signifi-
cance. Nevertheless, a significant correlation was observed
between plasma norepinephrine and dopamine concentra-
tions (r = 0.57, P < 0.05). The correlation between plasma
levels of norepinephrine and changes in cardiac index mea-
sured after the ingestion of levodopa was less impressive
than that noted with dopamine (r = 0.51, P < 0.05). More-
over, multiple linear regression analysis demonstrated that
the concentration of plasma dopamine was a signifi cant in-
dependent predictor of cardiac index measured after the
administration of levodopa, and that plasma norepinephrine
concentrations did not improve the ability to predict cardiac
index from plasma dopamine levels.
Clinical observations. The short-term oral administra-
tion of levodopa was associated with the development of
nausea and vomiting in three patients 45 to 90 minutes after
drug ingestion. These symptoms disappeared when the dose
of levodopa was reduced and did not recur when a more
gradual incremental dose schedule was used. No cardiac
arrhythmias and no electrocardiographic or clinical evidence
of myocardial ischemia developed during the study.
Cardiac index (liters/min per ml )
Heart rate (beats/min)
Stroke volume index
(mlibeal per ml )
Mean pulmonary capillary wedge
pressure (mm Hg)
Mean right atrial pressure (mm Hg)
Mean arterial pressure (mm Hg)
Systemic vascular resistance
(dynes-s-cm ~ )
Initial Study
2.07 ± 0. 12
90 ± 5
24 ± 2
23 ±
7 ± I
88 ± 3
1,842 ± 171
Long-Term
Study
2.03 ± 0. 15
81 ± 5*
26 ± 2
21 ± 2
6 :!: I
87 ± 4
1,872 ± 167
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the highest baseline plasma norepinephrine level (1,470 pg/
m!) in the study group.
Among the 13 patients who completed /2 weeks of treat-
ment with levodopa, there was no significant change in
diureticusage. Their body weightremained stable. Thedaily
dose of levodopawas decreased from 6 to 4 g in one patient
becauseof recurrentnausea and vomiting at the higherdose.
No motor or behavior disturbances developed in our pa-
tients.
Hemodynamic responses. Hemodynamic evaluation was
performed in 12 of the 13 patients after 12 weeks of treat-
ment with levodopa; I patient refused repeat right heart
catheterization. Baseline hemodynamic measurements ob-
tained during the long-term study were similar to the values
recorded before the administration of levodopain the initial
study, except for a significant decline in heart rate from
90 ± 5 to 81 ± 5 beats/min (p < 0.05) (Table 3). The
hemodynamic responses to levodopa in the patients receiv-
ing long-term treatment are shown in Table 4.
After drug ingestion, cardiac index rose from a baseline
value of 2.03 ± 0.15 liters/min per rrr' to a peak response
of 2.55 ± 0.26 (p < 0.0083) at 0.5 hour. The cardiac index
remained elevated throughout the study period. although it
was not significantly different from the control value6 hours
after the administration of levodopa. Similarly, the stroke
volume index increased from 26 ± 2 mllbeat per rrr' to a
maximum of 33 ± 3 at 0.5 hour (p < 0.0083); significant
improvement in the stroke volume index persisted for 3
hours. The systemic vascular resistance declined from
1,872 ± 167 dynes-s-cm - 5 to a nadir of \,505 ± 136 (p
< 0.0083) at 0.5 hour after drug administration and re-
mained significantly reduced for 6 hours. The mean arterial
pressure and heart rate were not altered appreciably. Sig-
nificant changes from the baseline mean atrial pressure of
6 ± I mm Hg were not observed after administration of
levodopa. Although there was a tendency for the mean pul-
monary capillary wedge pressure to decrease, the reduction
did not achieve statistical significance.
Plasma concentrations of dopamine and norepineph-
rine. As in the initial study, plasma dopamine concentra-
tions rose from a baseline value of 6.0 ± 1.1 ng/ml to a
peak valueof 41 ± 5 (p < 0.0083) at 0.5 hour after admin-
istration of levodopa. The plasma levels then declined grad-
ually, reaching a nadir of 15 ± 5 ng/ml at 6 hours. There
was a significant correlation between measurements of car-
diac index and plasma dopamine levels acquired during the
long-term study (r = 0.63, P < 0.05).
The plasma concentration of norepinephrine recorded
during the baseline period of the long-term study averaged
454 ± 75 pglml and was not significantly different from
thatdocumented during thecontrol periodof the initial study
(547 ± 124 pg/rnl). No appreciable alteration in plasma
norepinephrine levels occurred after ingestion of levodopa.
Changesincardiac indexmeasuredafter drug administration
failed to demonstrate a significant correlation with plasma
norepinephrine concentrations.
Discussion
Left ventricular performance after levodopa therapy.
The short-term oral administration of levodopa to patients
with congestive heart failure was associated with an im-
provement in left ventricular performance that persisted for
4 to 6 hours. Cardiac index and stroke volume index in-
creased and were accompanied by a decline in systemic
vascular resistance, mean pulmonary capillary wedge pres-
Table 4. Hemodynamic Measurements, Plasma Dopamine Levels and Plasma Norepinephrine Levels Obtained After Long-Term
Ingestion of Levodopa in 12 Patients
Hours After Levodopa Ingestion
Cardiac index
(liters /min per m2)
Heart rate (beats/min)
Stroke volume index
(nil/beat per m2)
Mean arterial pressure
(mm Hg)
SVR (dynes-s-cm -')
PCWP (mm Hg)
RAP (mm Hg)
Plasma dopamine
(ng/ml )
Plasma norepinephrine
(pg/rnl)
Basel ine
2.03 ± 0 .15
81 ± 5
26 ± 2
87 ± 4
1,872 :!: 167
21 :!: 2
6 ± I
6.0 :!: 1.1
454 ± 75
0.5
2.55 ± 0.26 *
81 ± 6
33 ± 3*
88 ± 4
1.505 ± 136*
21 :!: 2
7 ± I
41 ± 5*
553 ± 127
2.41 ± 0 .17 *
79 ± 6
32 ± 3*
85 ± 4
1,526 ± 117*
20 ± 2
6 ± I
24 ± 4*
426 ± 79
2
2.31 ± 0 .16 *
81 ± 6
30 ± 2*
82 ± 3
1.549 ± 107*
18 ± 2
6 ± I
33 ± 6*
534 ± 148
3
2.35 ± 0.15 *
79 ± 5
31 ± 2*
83 ± 4
1.529 ± 89*
19 ± 2
6 ± I
30 ± 7*
586 ± 141
4
2.25 ± 0 .10 *
80 ± 5
29 ± 2
82 ± 4
1.609 ± 85*
19 ± 2
6 ± I
21 ± 6*
503 ± l)7
6
2.23 ± 0 .10
82 ± 5
29 ± 2
83 ± 3
1,549 ± 74*
19 ± 2
6 ± I
15 ± 5
490 ± 107
Values are mean ± SEM . Abbreviations as in Table 2.
*p < 0.00 83 for the difference from the baseline value.
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sure and mean right atrial pressure. No significant change
in heart rate or systemic arterial pressure was observed.
After long-term ingestion of levodopa, similar changes in
cardiac index, stroke volume index and systemic vascular
resistance were observed. Moreover, a decline in heart rate
at rest occurred with long-term drug ingestion. These ob-
servations are consistent with a sustained beneficial effect
of levodopa on cardiac performance and are similar to mea-
surements documented in fi ve patients with heart failure in
our initial study (6).
Plasma dopamine levels and hemodynamic responses
to levodopa. A substantial elevation in plasma dopamine
levels occurred after the ingestion of levodopa during the
initial study period. This rise in plasma dopamine concen-
trations persisted after the long-term administration of le-
vodopa. A significant correlation was observed between
changes in cardiac index induced by levodopa and plasma
concentrations of dopamine during both the short- and long-
term studies. Although a modest correlation between plasma
norepinephrine concentrations and changes in cardiac index
was noted initially. multiple linear regression analysis re-
vealed that plasma norepinephrine levels did not improve
the ability to predict cardiac index from plasma dopamine
concentrations. These observations are consistent with the
hypothesis that the hemodynamic responses recorded in our
patients were determined primarily by dopamine generated
from levodopa.
Mechanisms of beneficial hemodynamic effects of le-
vodopa. The hemodynamic effects of levodopa can be at-
tributed to activation of beta--adrenoceptors and DA, re-
ceptors by dopamine derived from levodopa. The beta,-
adrenoceptor activity of dopamine is responsible for the
positive inotropic action of this catecholamine and can lead
to an increase in cardiac output accompanied by a reflex
withdrawal of the heightened vascular tone characteristic of
patients with heart failure (2 ,5,10, II ). Activation of DA,
vascular receptors leads to dilation of arterial vessels (2)
and thus a decline in peripheral vascular resistance results;
the reduction in left ventricular afterload can effect an in-
crease in cardiac performance. Studies conducted by our
group ( 12) have demonstrated that the administration of
dopamine to patients with dilated cardiomyopathy is asso-
ciated with an augmentation in left ventricular velocity of
fi ber shortening and a decline in left ventricular end-systolic
wall stress (an index of left ventricular afterload). With
dobutamine, which produces its hemodynamic effects pre-
dominantly through stimulation of beta.vadrenoceptors and
possesses no activity at dopamine receptors, an increase in
velocity of fiber shortening occurred and was not accom-
panied by a reduction in end-systolic wall stress. These
increments in velocity of fi ber shortening were adjusted to
eliminate the effects of altered loading conditions and thus
represent changes due solely to the positive inotropic action
of the drugs (13). Accordingly, it would appear that the
beneficial hemodynamic responses to levodopa can be at-
tributed not only to a positive inotropic action but also to
afterload reduction.
Role of plasma dopamine levels. The peak plasma con-
centrations of dopamine achieved with the doses of levodopa
ingested by our patients are similar to levels measured in
our laboratory during the intravenous administration of do-
pamine to subjects with heart failure at a rate of 2 JLg/kg
per min; these levels have averaged 63 ± 4 ng/ml (unpub-
lished observations). (Jamberg et al. [141 reported that the
mean plasma dopamine concentration was 28 ± 4 ng/ml
when dopamine was administered at a rate of 2 JLg/kg per
min to normal subjects.) In addition, the peak hemodynamic
responses to levodopa were similar to those observed when
we infused dopamine at a rate of 2 JLg/kg per min to another
group of patients with heart failure (5). We reported pre-
viously (12) that this infusion rate of dopamine produces a
substantial reduction in left ventricular end-systolic wall
stress and a modest increase in left ventricular velocity of
fiber shorte ning. Our findings imply that the hemodynamic
effects of levodopa at the doses utilized in the present study
were mediated by a marked decrease in left ventricular af-
terload in conjunction with a moderate positive inotropic
action.
Role of increased plasma norepinephrine levels. The
elevated plasma norepinephrine levels demonstrated in our
subjects arecharacteristic of patients with heart failure (15,16).
The increase in vascular resistance seen in heart failure has
been attributed in part to augmented sympathetic nervous
system activity (15). Therefore, activation of prejunctional
DA2 receptors, which produces a decrease in norepinephrine
release from sympathetic nerve endings (17), might be as-
sociated with an improvement in cardiac performance due
to a reduction in left ventricular afterload. Although do-
pamine possesses DA2 activity, plasma norepinephrinecon-
centrations did not decrease in our patients and actually
displayed a tendency to rise in parallel with plasma dopa-
mine levels during the initial hemodynamic study. The higher
plasma norepinephrine levels may reflect the release of neu-
rotransmitter from neuronal storage sites (18-20); the excess
dopamine levels do not appear to accelerate synthesis of
norepinephrine (18,2 1). With long-term ingestion of leva-
dopa, a decrease in neuronal stores of norepinephrine may
occur. In addition, activation of prejunctional alpha--adre-
noceptors by the elevated concentrations of norepinephrine
in the synaptic cleft can lead to a reflex decline in sympa-
thetic nerve activity (22); this negative feedback mechanism
serves to restore the local concentration of norepinephrine
(in the synaptic cleft) to baseline levels (22). The absence
of a rise in plasma levels of norepinephrine during the long-
term study period is consistent with this interpretation. In
any event. these observations suggest that the improvement
in cardiac performance produced by levodopa is probably
not due to the DA2 activity of dopamine.
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In contrast to the findings of the present study, a sustained
decline in plasma norepinephrine levels was documented in
patients with heart failure during long-term therapy with
ibopamine and occurred in association with an attenuation
of the initial hemodynamic responses to the drug (5). The
decrease in plasma norepinephrine concentrations can be
ascribed to the activation of prejunctional DA2 or alphar
adrenergic receptors, or both, on sympathetic nerve ter-
minals by N-methyldopamine (5). We postulated that the
reduction in sympathetic nerve activity may have led to an
up-regulation of beta 1- and alpha-adrenoceptors (23,24), the
densities of which have been reported to decrease in heart
failure (25,26). As a result, increased responsiveness to the
prominent postjunctional alpha-adrenoceptor activity
(produces vasoconstriction) of N-methyldopamine (27) could
then occur and counterbalance the vasodilating and modest
positive inotropic actions of the drug (28). The results of
hemodynamic studies (5) were consistent with this hypoth-
esis. These results suggested that more intense venocon-
striction and diminished arterial vasodilation were induced
by ibopamine after long-term administration to patients with
heart failure.
Precautions in levodopa administration. Activation of
alpha-adrenoceptors by dopamine may occur at moderate to
high infusion rates (typically at rates above 4 /Lg/kg per
min) (5). It is conceivable that in some patients the amount
of dopamine generated from levodopa may be sufficient in
magnitude to produce extensive activation of vascular alpha-
adrenoceptors, resulting in an increase in left ventricular
filling pressure and systemic vascular resistance. The latter
hemodynamic changes were observed by Shah et al. (29)
in one of their patients. This action of dopamine can be
blocked by the concomitant administration of an alpha-ad-
renoceptor antagonist (1). Nevertheless, it emphasizes the
need to titrate the dose of levodopa gradually. This approach
would also avoid excessive release of norepinephrine from
neuronal stores. Furthermore, substantial changes in the
protein content of the patient's diet should be avoided be-
cause levodopa and large neutral amino acids are absorbed
through a common active transport system in the gut (30);
a reduction in the amount of protein ingested can enhance
the bioavailability of levodopa (30,31).
Adverse effects of levodopa. The possibility that a de-
terioration in underlying cardiac function may result from
this therapeutic approach (32) is of particular concern during
long-term treatment with a positive inotropic agent. Baseline
hemodynamic measurements obtained during the short- and
long-term studies in our subjects did not reveal any dete-
rioration in cardiac performance. Moreover, a decrease in
heart rate was observed after long-term ingestion of levo-
dopa, which might result in a decrease in myocardial oxygen
demand during treatment. In accordance with this view, no
clinical evidence of myocardial ischemia developed in any
of our patients.
The most common adverse responses to levodopa ob-
served in our patients were nausea and vomiting. It has
been suggested that the emesis induced by levodopa is re-
lated to the activation of dopamine receptors located in the
chemoreceptor trigger zone by dopamine generated from
levodopa (33,34). The chemoreceptor trigger zone is located
on the peripheral side of the blood-brain barrier, and acti-
vation of dopamine receptors in this area is believed to be
the mechanism responsible for the emesis seen with selective
DA2 agonists, such as apomorphine and bromocriptine
(34,35). This hypothesis is supported by the report of Agid
et al. (35), who claim that domperidone, a selective antag-
onist of peripheral DA2 receptors, reduces the incidence of
nausea and vomiting associated with the ingestion of bromo-
criptine. However, this explanation is not consistent with
the rare occurrence of emesis with intravenous infusions of
dopamine, which does not traverse the blood-brain barrier
(1). Furthermore, patients still frequently develop nausea
and vomiting when levodopa is combined with a peripheral
aromatic amino acid decarboxylase inhibitor (36). Virtually
all commonly available antiemetic agents are both DA, and
DA2 receptor antagonists and, if they are ingested with
levodopa, attenuation of the hemodynamic responses to the
latter may occur. Metoclopramide, a DA receptor antagonist
that crosses the blood-brain barrier, may be effective in
limiting the incidence of emesis associated with levodopa
ingestion (37). Because metoclopramide blocks DA2 recep-
tors at a much lower concentration than that required to
antagonize activation of DA 1 receptors (37), we have cau-
tiously administered small doses (5 to 10 mg) of this drug
to patients with heart failure (not enrolled in the present
study) in whom emesis was associated with the ingestion
of levodopa. This regimen has been successful in treating
nausea and vomiting in several patients with no apparent
deterioration in their clinical status. Studies have been ini-
tiated to evaluate the efficacy and safety of this approach
to the treatment of emesis produced by levodopa in patients
with heart failure.
Clinical implications. The results of the present study
demonstrate that long-term administration of levodopa to
patients with heart failure is associated with sustained hemo-
dynamic improvement. Although our findings are encour-
aging, demonstration of beneficial hemodynamic responses
to levodopa in subjects with heart failure does not neces-
sarily predict that its administration to these patients will
prolong their survival or lead to an improvement in exercise
capacity (38,39). Placebo controlled trials assessing exercise
capacity are needed before widespread use of this drug can
be recommended.
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